Protocol Ledger

NCT07663903 · Phase III · ACTIVE NOT RECRUITING

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

Interventional Phase III clinical trial protocol NCT07663903 sponsored by Hangzhou Gensciences Biopharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-14 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07663903
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07663903
Protocol FieldVerified Registry Value
NCT IdentifierNCT07663903
Consolidated Lead SponsorHangzhou Gensciences Biopharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2026-04-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI